-
Mashup Score: 3Rebecca Lowe: Crystal Palace are my lifelong love. Winning the FA Cup would mean everything - 2 month(s) ago
NBC’s Premier League presenter will see her beloved Palace play for the first time in 12 years at Wembley as the club target a first trophy
Source: www.nytimes.comCategories: General Medicine NewsTweet
-
Mashup Score: 35CTG Labs - NCBI - 2 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: www.clinicaltrials.govCategories: General Medicine NewsTweet-
We have already enrolled 55 patients in 6 months on this study evaluating serial #PSMA #imaging in #BCR #ProstateCancer @theNCI Appreciate the support of referring docs who have sent us patients already & patients who have reached out Lots to learn https://t.co/d1vz4ahTTs https://t.co/AJpVGShGfG
-
-
Mashup Score: 25Immune Checkpoint Combos in Metastatic Castration-Resistant Prostate Cancer: Where Are We Going, What Are We Doing, and Why? - 4 month(s) ago
The mainstay of treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) remains a combination of androgen deprivation therapy along with standard-of-care androgen receptors signaling inhibitors and docetaxel as first-line chemotherapy, followed by cabazitaxel in the second-line setting. Efforts to enhance the efficacy of docetaxel has included a variety of biologic and radioactive agents in addition to the combination of chemotherapy with immune checkpoint inhibitors (ICIs),
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Dr. Susan Slovin @MSKCancerCenter asks some key questions regarding #ProstateCancer #Immunotherapy @JCO_ASCO @ASCO @urotoday #Immune #Checkpoint Combos in mCRPC: Where Are We Going, What Are We Doing, and Why? https://t.co/hDra85uykF
-
-
Mashup Score: 39
e16587Background: In patients with BRPC after RP, PSADT is the strongest determinant of metastasis-free and overall survival. Prior reports defined 4 broad PSADT subgroups that predicted MFS and OS (15 mo). Prostate cancer specific …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Since #EMBARK data there is a need to define high risk #BCR #ProstateCancer Best data I have seen comes from @HopkinsMedicine team Risk of mets at 5 years is only 26% for #PSA DT 6-9 months. Significantly lower risk than DT 3-6 mos or DT under 3 mos https://t.co/Uu1KGadxTb https://t.co/Jcmmfq7Afa
-
-
Mashup Score: 46Program Guide – ASCO Meeting Program Guide - 5 month(s) ago
Ravi Madan Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health Ravi Madan , Melissa Abel , Esther Mena , Liza Lindenberg , Megan Hausler , Monique Williams , Amy Hankin , Jeanny Aragon-Ching , Laura Sena , Russell Pachynski , Edwin Posadas , Helen Moon , Marijo Bilusic , Philip Arlen , Krishnan Patel , Deborah Jolissaint , Gregory Chesnut , William Figg , Fatima Karzai , Peter Choyke Genitourinary Malignancies Branch, Center for Cancer
Source: meetings.asco.orgCategories: General Medicine News, Hem/OncsTweet-
Abs#45 @asco #GU25 Prelim data shows near term metastatic progression (conventional imaging) is a rare event in #PSMA+ #BCR #ProstateCancer Are we overtreating pts w/ median age of 70+ based on lack of understanding of #PSMA? This study continues… https://t.co/7hwIxW2ra9 https://t.co/xwoH5X5Ebs
-
-
Mashup Score: 25Program Guide – ASCO Meeting Program Guide - 5 month(s) ago
Melissa Abel , Fatima Karzai , Philip Arlen , Clara Chen , Esther Mena , Liza Lindenberg , Jeanny Aragon-Ching , Lisa Cordes , Katherine Lee-Wisdom , Amy Hankin , Monique Williams , Yolanda McKinney , James Gulley , William Figg , Peter Choyke , Ravi Madan National Institutes of Health, National Cancer Institute, National Institutes of Health, Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Molecular Imaging Branch, National Cancer Institute, National Institutes
Source: meetings.asco.orgCategories: General Medicine News, Hem/OncsTweet-
Ab#180 @asco #GU25 Dr. Melissa Abel @melissaabel20 @theNCI #Radium in PET+ CT/bone scan negative #BCR #ProstateCancer Changes on PET scans & PSA declines observed Rare Gd1/2 toxicity No 🚫anemia or thrombocytopenia (Unlike other studies w/SBRT) https://t.co/gcU0miFnmk https://t.co/jgQECpPRVn
-
-
Mashup Score: 46Program Guide – ASCO Meeting Program Guide - 5 month(s) ago
Ravi Madan Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health Ravi Madan , Melissa Abel , Esther Mena , Liza Lindenberg , Megan Hausler , Monique Williams , Amy Hankin , Jeanny Aragon-Ching , Laura Sena , Russell Pachynski , Edwin Posadas , Helen Moon , Marijo Bilusic , Philip Arlen , Krishnan Patel , Deborah Jolissaint , Gregory Chesnut , William Figg , Fatima Karzai , Peter Choyke Genitourinary Malignancies Branch, Center for Cancer
Source: meetings.asco.orgCategories: General Medicine News, Hem/OncsTweet-
Abs#45 @asco #GU25 Prelim data shows near term metastatic progression (conventional imaging) is a rare event in #PSMA+ #BCR #ProstateCancer Are we overtreating pts w/ median age of 70+ based on lack of understanding of #PSMA? This study continues… https://t.co/7hwIxW2ra9 https://t.co/xwoH5X5Ebs
-
-
Mashup Score: 25
e16587Background: In patients with BRPC after RP, PSADT is the strongest determinant of metastasis-free and overall survival. Prior reports defined 4 broad PSADT subgroups that predicted MFS and OS (15 mo). Prostate cancer specific …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Since #EMBARK data there is a need to define high risk #BCR #ProstateCancer Best data I have seen comes from @HopkinsMedicine team Risk of mets at 5 years is only 26% for #PSA DT 6-9 months. Significantly lower risk than DT 3-6 mos or DT under 3 mos https://t.co/Uu1KGadxTb https://t.co/Jcmmfq7Afa
-
-
Mashup Score: 17EAU 2021: Treatment Options for De-Novo mHSPC: Future: Personalized Medicine for mHSPC? - 7 month(s) ago
EAU 2021 personalized medicine for mHSPC, treatment for metastatic hormone-sensitive prostate cancer, PROfound trial, personalized medicine in advanced prostate cancer, de novo mHSPC patients, VISION trial.
Source: www.urotoday.comCategories: General Medicine News, Hem/OncsTweet-
Study design via @urotoday #CAPItello-281 Phase III trial https://t.co/A3J99BzAif https://t.co/V8G9NOPRn8 https://t.co/U1zX4whWLG
-
-
Mashup Score: 17EAU 2021: Treatment Options for De-Novo mHSPC: Future: Personalized Medicine for mHSPC? - 7 month(s) ago
EAU 2021 personalized medicine for mHSPC, treatment for metastatic hormone-sensitive prostate cancer, PROfound trial, personalized medicine in advanced prostate cancer, de novo mHSPC patients, VISION trial.
Source: www.urotoday.comCategories: General Medicine News, Hem/OncsTweet-
Study design via @urotoday #CAPItello-281 Phase III trial https://t.co/A3J99BzAif https://t.co/V8G9NOPRn8 https://t.co/U1zX4whWLG
-
@AdamSharpMedOnc Come on you #Palace!!! 🦅#cpfc #FACupFinal 🦅 Great read for what this means for the great fans of this club by the one and only Rebecca Lowe https://t.co/URdbrVnGPg